Why Pathway Genomics is on defensive

[Anonymous]

The Managers that frequently come one the board spewing and ranting are worried about a lot of things. Uncertainty in the business and at Pathway Genomics, naturally they are going to blame everyone else.

MISLEADING MARKETING OF GENETIC TESTS


Will the Genome Become the Source of Diagnostic Miracles or Potential Scams?
by Helen Wallace

Marketing of genetic susceptibility tests both via doctors and direct-to-consumers is growing in the USA and in Europe. Companies have a powerful financial incentive to sell not only genetic tests but associated advice and individually tailored products, including skin creams, supplements, medicines and foods (what they call “nutrigenomics”).

However, strong associations between genes and susceptibility to common diseases found in early studies are typically not confirmed by larger, later ones. Most of these genetic tests will therefore be misleading and the associated products and advice are, at best, a waste of money. At worst, they may also be harmful to health.

 

[Anonymous]

They are on the defensive because genetics testing giant Myriad Genetics is suing them for their misleading marketing tactics. Where is this $10 million in free genetic testing for women in need? LMAO

NO INVESTORS WILL COME NEAR PATHWAY GENOMICS WHILE THEY ARE INVOLVED WITH A LAWSUIT.

Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status

SAN DIEGO, CA – June 16, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.


“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.

Pathway Genomics recently began offering BRCATrueTM, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for OneTM program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”

BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

FALSE CLAIMS BY PATHWAY GENOMICS

I WON'T RESORT TO NAME CALLING AS PATHWAY DOES - LETS LEAVE IT TO MYRIAD FOR THAT AND LET THE FUR FLY IN THIS CAT FIGHT. I REALLY HOPE THEY CAN GET IT TOGETHER AND GET THROUGH THIS LAWSUIT. (SNICKER)

 

[Anonymous]

Do you think posting multiple threads about pathway is going to hurt them? Can you not keep this all in one thread? You seem unstable.

 

[Anonymous]

What's with the all cap's sentences and abbreviations like LMFAO? Can you please keep it professional? I feel like I'm reading teen beat magazine articles.

 

[Anonymous]

What's with the all cap's sentences and abbreviations like LMFAO? Can you please keep it professional? I feel like I'm reading teen beat magazine articles.

he he,it must really bother you the amount of times you troll and patrol this board.

this is great stuff, this poster is shitting their pants.

 

[Anonymous]

What's with the all cap's sentences and abbreviations like LMFAO? Can you please keep it professional? I feel like I'm reading teen beat magazine articles.

Is that all the better you can do is try to hijack our board with your stupid grammar corrections.

I am worried, this is not the company I thought I signed up for. Glad you are not my boss, he is smart. You are scarying me more than this lawsuit thingy, the poster that mentioned legal fees is right. One of my last companies was also involved in a bad lawsuit, it was expensive close to $1.5 million in fees and 2.6 years latter and no judgment.

Whatever, my eyes are wide open for me and my family.

 

[Anonymous]

Is that all the better you can do is try to hijack our board with your stupid grammar corrections.

I am worried, this is not the company I thought I signed up for. Glad you are not my boss, he is smart. You are scarying me more than this lawsuit thingy, the poster that mentioned legal fees is right. One of my last companies was also involved in a bad lawsuit, it was expensive close to $1.5 million in fees and 2.6 years latter and no judgment.

Whatever, my eyes are wide open for me and my family.

Bottom line that is what everyone should be doing is watching out for you and your family. PG doesn't care, the would rather spend thousands in legal fees defending some lawsuit than pay you a decent commission plan.

 

[Anonymous]

They are on the defensive because genetics testing giant Myriad Genetics is suing them for their misleading marketing tactics. Where is this $10 million in free genetic testing for women in need? LMAO

NO INVESTORS WILL COME NEAR PATHWAY GENOMICS WHILE THEY ARE INVOLVED WITH A LAWSUIT.

Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status

SAN DIEGO, CA – June 16, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.


“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.

Pathway Genomics recently began offering BRCATrueTM, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for OneTM program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”

BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

FALSE CLAIMS BY PATHWAY GENOMICS

I WON'T RESORT TO NAME CALLING AS PATHWAY DOES - LETS LEAVE IT TO MYRIAD FOR THAT AND LET THE FUR FLY IN THIS CAT FIGHT. I REALLY HOPE THEY CAN GET IT TOGETHER AND GET THROUGH THIS LAWSUIT. (SNICKER)

Why is Myriad even bring this lawsuit? Pathway only test for BRAC 1 and 2. No provider in his or her right mind would order this test! Pathway's test cannot match any of the competition product offering.

 

[Anonymous]

Why is Myriad even bring this lawsuit? Pathway only test for BRAC 1 and 2. No provider in his or her right mind would order this test! Pathway's test cannot match any of the competition product offering.

Let me correct this before K'Lene does. I believe the poster meant to say Bringing, in Bring. The point was achieved. T